# John D. Powderly

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-d-powderly/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,799 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 46 |
| i10-index | 106 |
| Last Known Institution | Carolina BioOncology Institute |
| OpenAlex ID | https://openalex.org/A5090977453 |
| ORCID iD | https://orcid.org/0000-0002-7608-0380 |
| Works | 309 |

## Researcher papers

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates](https://scholariq.org/papers/phase-i-study-of-single-agent-anti-programmed-death-1-mdx-1106-in-refractory/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study](https://scholariq.org/papers/five-year-follow-up-of-nivolumab-in-previously-treated-advanced-non-small-cell/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Carolina BioOncology Institute](https://scholariq.org/institutions/carolina-biooncology-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.